November 30, 2020

The Niche

Knoepfler lab stem cell blog

Osiris success with Diabetic foot ulcers is a giant step

Osiris TherapeuticsStem cell & cellular medicine biotech, Osiris, reported a major success today with its cell-based treatment of Diabetic foot ulcers. The data are about as good as it gets.

The company’s Grafix product for the ulcers was three times more effective than the control. A cross-over phase where those given the control were switched to Grafix showed similarly dramatic results.

Wounds that won’t heal are a huge health problem in medicine so Osiris’ impressive results have huge implications. I see this also more broadly as a giant step forward for the cellular medicine field. The stock (OSIR) more than doubled so far today in PPS.

Note: I changed the title & some content from the original version of the post focused on the “stem cell” field to the “cellular medicine” field out of an abundance of caution.

Disclosure: I do not own any stock in Osiris. 

%d bloggers like this: